Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune is a clinical-stage biotechnology company that is focused on developing innovative treatments for neurodegenerative diseases. The company's proprietary technology platforms allow them to design and develop specific therapies for diseases such as Alzheimer's and Parkinson's. With a strong pipeline consisting of multiple active immunotherapy programs targeting different proteins involved in neurodegeneration, AC Immune is well-positioned to potentially make a significant impact in the treatment landscape for these devastating diseases. The company also has a versatile platform for the development of small-molecule imaging agents and maintenance therapy, which could provide additional value and potential revenue streams. Overall, AC Immune appears to be a promising company with a strong potential for growth in the future.

Bears say

AC Immune is heavily focused on discovering and developing products targeting misfolded proteins, which could be a risky and potentially unreliable approach in the ever-changing landscape of neurodegenerative diseases. This is highlighted by the fact that their pipeline mainly consists of early-stage drugs with no guarantees of success. Additionally, while the potential exercise fee from Takeda could provide a boost to their financials, it ultimately depends on the success of the ACI-24.060 drug and is not a guaranteed source of revenue.

AC Immune (ACIU) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 1 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.